HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4+ Th1 cell responses in vivo

Vaccine

Volumn 24, Issue 26, 2006, Pages 5491-5497

  Gao, Ming ^a,b   Wang, Hai Ping ^a   Wang, Yan Ning ^b   Zhou, Yong ^a   Wang, Quan Li ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Lanzhou Jingcheng Hospital   (China)

Author keywords

CD4+ Th cell; Gene vaccine; Hepatitis C virus; Invariant chain

Indexed keywords

CLASS II ASSOCIATED INVARIANT CHAIN PEPTIDE; GAMMA INTERFERON; GLYCYLTYROSYLLYSYLVALYLLYSYLVALYLLYSYLASPARAGINYLPROLYLSERYLVALLYLALANYL ALANYLTHREONINE; NONSTRUCTURAL PROTEIN 3; PROTEIN DERIVATIVE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; ASSAY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMORAL IMMUNITY; IMMUNIZATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TH1 CELL; TUMOR CELL;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; EPITOPES; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HISTOCOMPATIBILITY ANTIGENS CLASS II; MICE; MICE, INBRED BALB C; RNA; VACCINES, DNA; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 33744928864     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.04.004     Document Type: Article

References (29)

1. Koff R.S. Hepatitis vaccines: recent advances. Int J Parasitol 33 (2003) 517-523
2. Steven R. Recent advances in the molecular biology of hepatitis C virus. J Mol Biol 313 (2001) 451-464
3. Reichard O., Norkrans G., Fryden A., Braconier J.H., Sonnerborg A., and Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 351 (1998) 83-87
4. Schvarcz R., Ando Y., Sonnerborg A., and Weiland O. Combination treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 23 (1995) 17-21
5. Ferrari C., Valli A., Galati L., Penna A., Scaccaglia P., and Giuberti T. T cell response to structural and non-structural hepatitis C virus antigen in persistent and self-limited hepatitis C virus infection. Hepatology 19 (1994) 286-295
6. Diepolder H.M., Zachoval R., Hoffmann R.M., Wierenga E.A., Santantonio T., Jung M.C., et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346 (1995) 1006-1007
7. Missale G., Bertoni R., Lamonaca V., Valli A., Massari M., Mori C., Rumi M.G., Houghton M., Fiaccadori F., and Ferrari C. Diffrent clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98 (1996) 706-714
8. Tsai S.L., Liaw Y.F., Chen M.H., Huang C.Y., and Kuo G.C. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25 (1997) 449-458
9. Cramp M.E., Rossol S., Chokshi S., Carucci P., Williams R., and Naoumov N.V. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118 (2000) 346-355
10. Zhang Z.X., Milich D.R., Peterson D.L., Birkett A., Schvarcz R., Weiland O., and Sallberg M. Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of therapy. J Infect Dis 175 (1997) 1294-1301
11. Bartenschlager R., Lohmann V., Wilkinson T., and Koch J.O. Complex formation between the NS3 serine-type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J Virol 69 (1995) 7519-7528
12. Failla C., Tomei L., and De Francesco R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol 68 (1994) 3753-3760
13. Jin L., and Peterson D.L. Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase. Arch Biochem Biophys 323 (1995) 47-53
14. Busch R., Doebele R., Patil N.S., Pashine A., and Mellins E.D. Accessory molecules of MHC class II peptide loading. Curr Opin Immunol 12 (2000) 99-106
15. Nakano N., Rooke R., Benoist C., and Mathis D. Positive selection of T cells induced by viral delivery of neopeptides to the thymus. Science 275 (1997) 678-683
16. van Bergen J., Schoenberger S.P., Verreck F., Amons R., Offringa R., and Koning F. Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP. Proc Natl Acad Sci USA 94 (1997) 7499-7502
17. Fujii S., Senju S., Chen Y.Z., Ando M., Matsushita S., and Nishimura Y. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells. Hum Immunol 59 (1998) 607-614
18. Malcherek G., Wirblich C., Willcox N., Rammensee H.G., Trowsdale J., and Melms A. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation. Eur J Immunol 28 (1998) 1524-1533
19. Sponaas A., Carstens C., and Koch N. C-terminal extension of the MHC class II-associated invariant chain by an antigenic sequence triggers activation of naive T cells. Gene Ther 6 (1999) 1826-1834
20. Gao M., Wang H.P., Wang Y.N., Zhou Y., and Wang Q.L. Target HCV NS3 CD4+ Th1 epitope to major histocompatibility complex class II pathway. Biotech Lett 28 (2006) 3-8
21. Sambrook J., Fritsch E.F., and Maniatis. Molecular cloning, a laboratory manual. 2nd ed. (1989), Cold Spring Harbor Laboratory Press p. 24-28
22. Pape G.R., Gerlach T.J., Diepolder H.M., et al. Role of the specific T-cell response for clearance and control of hepatitis C virus. J Viral Hepatol 6 Suppl. 1 (1999) 36-40
23. Thimme R., Oldach D., Chang K.M., et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194 (2001) 1395-1406
24. Thimme R., Bukh J., Spangenberg H.C., et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 99 (2002) 15661-15668
25. van Tienhoven E., ten Brink C., van Bergen, et al. Induction of antigen specific CD4+ T cell responses by invariant chain based DNA vaccines. Vaccine 19 (2001) 1515-1519
26. Nagata T., Higashi T., Aoshi T., et al. Immunization with plasmid DNA encoding MHC class II binding peptide/CLIP-replaced invariant chain (Ii) induces specific helper T cells in vivo: the assessment of Ii p31 and p41 isoforms as vehicles for immunization. Vaccine 20 (2002) 105-114
27. + T cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 71 8 (1997) 6011-6019
28. Xu J.J., Wang T., Qi L.Q., et al. The study of a helper T-cell epitope in hepatitis C virus non-structural 3 protein. Zhongguo Bingduxue 15 (2000) 318-322
29. Yu H., Huang H., Xiang J., Babiuk L.A., and Little-van den Hurk S. Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3. J Gen Virol 87 (2006) 1-10